Publications by authors named "Vasyl Kishchuk"
Article Synopsis
- Scleroma, caused by Klebsiella pneumoniae, is a rare chronic disease affecting the upper respiratory tract, with unclear causes and numerous immune system disturbances.
- A study analyzed the local immunity in the oropharynx of 92 scleroma patients and 20 healthy individuals, measuring several immune factors in their oropharyngeal secretions.
- The results showed significant decreases in secretory and monomeric immunoglobulins in scleroma patients, indicating a deficiency in local immunity that may contribute to the chronic inflammation seen in the disease, suggesting a need for immune therapy in treatment.
Objective: Introduction: At present biocomposite materials are used in the surgical treatment of frontal bone fracture. They improve osteogenesis, reduce the number of complications. Immunologic aspects of application of these materials are studied insufficiently, therefore this report presents the results of immunoassay of patients with frontal bone fracture in the proximate posttraumatic period before implanting preparation "Syntekost".
View Article and Find Full Text PDFObjective: Introduction: The problem of bone tissue regeneration and the development of the methods of directional influence on bone healing processes are one of the most urgent problems of modern medicine. The question of bone tissue posttraumatic regeneration is particularly important with regard to military conflicts, ecological and technological disasters, and has social and economic relevance, connected with the necessity of long-term treatment and medical rehabilitation. The aim: The objective of the work is the experimental evaluation of bone tissue reparative regeneration during the implantation of biocomposite "Syntekost" (patent for invention №98573 dated 25.
View Article and Find Full Text PDFObjective: To investigate the effectiveness and safety of the homeopathic product SilAtro-5-90 in recurrent tonsillitis.
Methods: In this international, pragmatic, controlled clinical trial, 256 patients (6-60 years) with moderate recurrent tonsillitis were randomized to receive either SilAtro-5-90 in addition to standard symptomatic treatment, or to receive standard treatment only. The primary outcome was the mean time period between consecutive acute throat infections (ATI) within 1 year (analyzed via repeated events analysis).